Last Updated : August 7, 2025
Details
FilesGeneric Name:
pertuzumab
Project Status:
Active
Therapeutic Area:
HER2+ breast cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0379-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Submission Complexity:
Standard Review
Fee Schedule:
Pending
Indications:
In combination with trastuzumab and chemotherapy for early stage HER2+ breast cancer in the neoadjuvant setting.
| Review initiated | February 14, 2025 |
|---|---|
| Expert committee meeting (initial) | July 17, 2025 |
Files
Last Updated : August 7, 2025